Liver cirrhosis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PNPLA3 1
• SGLT2 1
• BCL-2 0
• PPAR 0
• PSMA 1

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Evaluation of Accuvein in Cirrhotics Patients

  NCT03996135· University Hospital, Caen· Updated 12 Nov 2026

  “availability of the principal investigator”Registry text, quoted unchanged. Source

• Terminated

  Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

  NCT05516498· AstraZeneca· Updated 25 Sept 2026

  “The study was ended earlier than planned due to a sponsor decision.”Registry text, quoted unchanged. Source

• Terminated

  NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients

  NCT06000748· University of California, San Francisco· Updated 24 Sept 2026

  “Investigator Left Institution”Registry text, quoted unchanged. Source

• Terminated

  Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response

  NCT07102979· Chang Gung Memorial Hospital· Updated 6 Aug 2026

  “Slow recruitment and exhaustion of available study funding.”Registry text, quoted unchanged. Source

• Terminated

  Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

  NCT05900050· Genfit· Updated 23 Jul 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Galectin Therapeutics Inc.· Updated 30 Jun 2026

  “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.”Registry text, quoted unchanged. Source

• Terminated

  Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function

  NCT02626312· M.D. Anderson Cancer Center· Updated 17 Jun 2026

  “\< 75% participation”Registry text, quoted unchanged. Source

• Terminated

  Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

  NCT05027425· University of Cincinnati· Updated 6 May 2026

  “The study is closing due to low enrollment and feasibility of the study.”Registry text, quoted unchanged. Source

• Terminated

  Extracellular RNA Markers of Liver Disease and Cancer

  NCT02908048· Mayo Clinic· Updated 5 May 2026

  “Ran out of funds”Registry text, quoted unchanged. Source

• Suspended

  4beta-hydroxycholesterol in Cirrhosis

  NCT04199910· University of Oulu· Updated 5 May 2026

  “COVID pandemia and organisational changes hinder recruitment”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)

  NCT07933328· Regeneron Pharmaceuticals· Source

• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Boehringer Ingelheim· Source

• Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  NCT07631637· Regeneron Pharmaceuticals· Source

• A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

  NCT06096779· Genentech, Inc.· Source

• A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07701993· GlaxoSmithKline· Source

• A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07704892· GlaxoSmithKline· Source

• Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

  NCT07610837· AstraZeneca· Source

• Nitazoxanide in Spontaneous Bacterial Peritonitis

  NCT07808450· Tanta University· Source

• A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

  NCT05809934· AstraZeneca· Source

• Evaluation of Non-Invasive Tests for Metabolic Liver Disease

  NCT07122700· Foundation for the National Institutes of Health· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.